FDA Recalls Tiagabine Hydrochloride Tablets Due to Impurity Specification Failures
Sun Pharmaceutical is recalling Tiagabine Hydrochloride Tablets (2 mg) due to out-of-specification impurities detected during testing. The recall affects lot HAC3339A distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II prescription drug recall involves detection of out-of-specification impurities, which represents a risk-of-harm product. No illnesses or injuries have been reported.
Plain-English summary
Sun Pharmaceutical Industries Inc is recalling Tiagabine Hydrochloride Tablets, 2 mg, distributed nationwide in the United States. The recall affects approximately 8,880 bottles containing 30 tablets each from lot HAC3339A, which expires July 2023.
The recall was initiated because out-of-specification impurities were detected during Related Substances testing. The impurity levels exceeded the established quality standards for this medication.
Patients who have the affected lot should consult their healthcare provider or pharmacist for guidance regarding their medication supply. The affected lot number, HAC3339A, appears on the bottle label.
The recalled product
- Product
- TIAGABINE HYDROCHLORIDE (TIAGABINE HYDROCHLORIDE)
- Brand
- TIAGABINE HYDROCHLORIDE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot HAC3339A
- Expires 07/2023
UPCs (2)
- 0362756200838
- 0362756224834
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17